Taspoglutide (ITM077)是一种新型人胰高血糖素样肽-1类似物 [hGLP-1(7–36)NH₂]，目前正在用于2型糖尿病的临床开发。Taspoglutide是hGLP-1 的结构衍生物，在Ala8和Gly35位点引入α-氨基异丁酸（Aib）取代。在CHO细胞中，Taspoglutide可抑制VEGFR2，其IC₅₀值为4.6±0.6nM。
Cas No.:275371-94-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Taspoglutide (ITM077) is a novel analog of human glucagon-like peptide-1 [hGLP-1(7-36)NH2] in clinical development for the treatment of type 2 diabetes. Taspoglutide inhibits VEGFR2 in CHO cells with an IC50 value of 4.6±0.6nM[1,2]. Taspoglutide is a structural derivative of hGLP-1 with α-aminoisobutyric acid (Aib) substitutions replacing Ala8 and Gly35[1].
In vitro, Taspoglutide (0.001-100nM) stimulates insulin secretion in a glucose-dependent manner, enhancing secretion at high glucose (16.7mM) even at very low concentrations (0.001nM) in INS-1E rat insulinoma cells[1].
In vivo, Taspoglutide (0.4mg; s.c.; once-monthly for 12 weeks) significantly decreased food intake and body weight in hyperglycemic ApoE-/- mice[3]. Taspoglutide (0.4mg; s.c.; once-monthly for 12 weeks) treatment significantly increased levels of mRNA transcripts for the transcription factor liver X receptor (Lxr) as well as multiple LXR target genes, Abca1, Abcg5, Abcg1, and Abcg8, involved in cholesterol shuttling and clearance. Taspoglutide (0.4mg; s.c.; once-monthly for 12wk) also increased mRNA levels for hepatic lipase (Hl), a key enzyme in the regulation of triglyceride storage and clearance, as well as Cpt1a, a ratelimiting mitochondrial fatty acid carrier regulating the rate of free fatty acid β-oxidation in hyperglycemic ApoE-/- mice[3]. Taspoglutide Treatment (1mg; s.c.; once) significantly reduced proliferating pancreatic β-cells per islet cross-section in ZDF rats[4].
References:
[1]. Sebokova, Elena, et al. "Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency." Endocrinology 151.6 (2010): 2474-2482.
[2]. Rosenstock, Julio, et al. "The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial." Diabetes care 36.3 (2013): 498-504.
[3]. Panjwani, Naim, et al. "GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE−/− mice." Endocrinology 154.1 (2013): 127-139.
[4]. Uhles, S., et al. "Taspoglutide, a novel human once‐weekly GLP‐1 analogue, protects pancreatic β‐cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo." Diabetes, Obesity and Metabolism 13.4 (2011): 326-336.
Taspoglutide (ITM077)是一种新型人胰高血糖素样肽-1类似物 [hGLP-1(7–36)NH₂]，目前正在用于2型糖尿病的临床开发。Taspoglutide是hGLP-1的结构衍生物，在Ala8和Gly35位点引入α-氨基异丁酸（Aib）取代[1]。在CHO 细胞中，Taspoglutide可抑制VEGFR2，其IC₅₀值为4.6±0.6nM[1]。
在体外实验中，Taspoglutide（0.001–100 nM）可呈葡萄糖依赖性地促进胰岛素分泌，在INS-1E大鼠胰岛瘤细胞中，即使在极低浓度（0.001nM）时，在高糖（16.7mM）条件下仍可显著增强胰岛素分泌[1]。
在体内实验中，Taspoglutide（0.4mg，皮下注射，每月一次，持续12周）可显著降低高血糖ApoE⁻/⁻小鼠的食物摄入量和体重[3]。给予Taspoglutide（0.4mg，皮下注射，每月一次，持续12周）可显著上调转录因子肝X受体（Lxr）以及多个参与胆固醇转运和清除的 LXR 靶基因（Abca1、Abcg1、Abcg5 和 Abcg8）的mRNA表达水平。此外，Taspoglutide 还可上调肝脂肪酶（Hl）（调控甘油三酯代谢的关键酶）以及肉碱棕榈酰转移酶1A（Cpt1a）（参与脂肪酸β-氧化的线粒体限速转运蛋白）的 mRNA 表达水平[3]。在ZDF大鼠中，Taspoglutide（1mg，皮下注射，单次给药）可显著减少每个胰岛横截面中处于增殖状态的胰腺β细胞数量[4]。
| Cell experiment [1]: | |
Cell lines | MIN6B1 cells |
Preparation Method | MIN6B1 cells were cultured for 24h in MIN6 medium (DMEM-based) pH 7.0. The medium was then replaced by serum-free and low glucose (5mmol/l) MIN6 medium pH 7.0 containing 0, 0.1, 1, 10 or 100nM Taspoglutide. |
Reaction Conditions | 0, 0.1, 1, 10 or 100nM; 48h.0, 0.1, 1, 10 or 100nM; 48h. |
Applications | Taspoglutide stimulated the proliferation of dispersed islet cell. |
| Animal experiment [2]: | |
Animal models | Four-week-old male ApoE-/- mice |
Preparation Method | Four-week-old male ApoE-/- mice were started on a high-fat (45% kcal) diet. Modest hyperglycemia was induced using STZ (an initial dose of 75mg/kg followed by a second dose of 125mg/kg 10d later), and mice with glucose levels from 15-25mM were then randomized to different groups and treated for 12 weeks with a once-monthly s.c. 0.4mg Taspoglutide microtablet suspension, a s.c. placebo microtablet, or metformin (400mg/kg·d) continuously provided in the drinking water plus a s.c placebo microtablet. |
Dosage form | 0.4mg; s.c.; once-monthly for 12 weeks. |
Applications | Taspoglutide significantly decreased food intake and body weight. |
References: | |
| Cas No. | 275371-94-3 | SDF | |
| 别名 | 他司鲁泰,ITM077; R1583; BIM51077 | ||
| Canonical SMILES | [H-{Aib}-EGTFTSDVSSYLEGQAAKEFIAWLVK-{Aib}-R-NH2] | ||
| 分子式 | C152H232N40O45 | 分子量 | 3339.71 |
| 溶解度 | DMSO : ≥ 28 mg/mL (8.38 mM) | 储存条件 | Store at -20°C,Sealed storage, away from moisture and light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 299.4 μL | 1.4971 mL | 2.9943 mL |
| 5 mM | 59.9 μL | 299.4 μL | 598.9 μL |
| 10 mM | 29.9 μL | 149.7 μL | 299.4 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet